Laurențiu Scheușan, who has been recently appointed as head over a seven-country region with Alvogen US drug maker, says Romania has become a regional centre for the company, meaning the activity in this area will be coordinated from the domestic market.
Last year, the first operational year for the company in
Romania, turnover hit 1.9m dollars, while for this year the target
was raised to 6m dollars.
Scheușan wants Romanian turnover to reach 35-30m dollars in
2015.
“There will be organic growth, but as competition is very tight at
present, if we want to grow we must also consider acquisitions.
However, there will not be large acquisitions and we target
medium-sized companies. In Romania, I looked (to buy a company),
but I haven’t found any opportunity to present to the board,”
Scheușan, sales executive vice-president in CEE with Alvogen, told
ZF.
“(…) Unfortunately, I have no argument to present to the board
for a greenfield investment in Romania (…),” Scheușan said.